The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press14010.17650/1818-8338-2014-1-4-8EDITORIALРЕДАКЦИОННАЯ СТАТЬЯNEW MARKERS FOR CARDIOVASCULAR RISK: FROM STUDIES TO CLINICAL GUIDELINESНОВЫЕ МАРКЕРЫ СЕРДЕЧНО-СОСУДИСТОГО РИСКА: ОТ ИССЛЕДОВАНИЙ К КЛИНИЧЕСКИМ РЕКОМЕНДАЦИЯМAnichkovD. A.АничковД. А.
Russian Federation
d.anichkov@gmail.comShostakN. A.ШостакН. А.
Russian Federation
Acad. A.I. Nesterov Department of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, MoscowКафедра факультетской терапии им. акад. А.И. Нестерова, ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва1501201481482311201423112014Copyright ©; 2014, Anichkov D.A., Shostak N.A.Copyright ©; 2014, Аничков Д.А., Шостак Н.А.2014Anichkov D.A., Shostak N.A.Аничков Д.А., Шостак Н.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/140

New markers for cardiovascular disease (CVD) risk are the subject of an intensive discussion in the scientific literature. The biomarkers (newlipid parameters, inflammatory markers) and signs of subclinical atherosclerosis are candidates to be included in models to assess the cumulative risk of CVD. The paper considers the basic studies dealing with new markers of CVD risk and their place in current clinical recommendations.

Новые маркеры риска сердечно-сосудистых заболеваний (ССЗ) – предмет интенсивного обсуждения в научной литературе. Биомаркеры (новые липидные параметры, маркеры воспаления) и признаки субклинического атеросклероза – кандидаты на включение в модели оценки суммарного риска ССЗ. В статье рассматриваются основные исследования, посвященные новым маркерам риска ССЗ, а также их место в современных клинических рекомендациях.

cardiovascular diseasespreventionrisk rating scalesbiomarkersclinical guidelinesсердечно-сосудистые заболеванияпрофилактикашкалы оценки рискабиомаркерыклинические рекомендации1. Киселев А.Р., Нейфельд И.В., Балашов С.В. Факторы сердечно-сосудистого риска у женщин в постменопаузе. Клиницист 2014;(1):9–14.Киселев А.Р., Нейфельд И.В., Балашов С.В. Факторы сердечно-сосудистого риска у женщин в постменопаузе. Клиницист 2014;(1):9–14.2. Маркин А.В., Мартыненко Т.И., Костюченко Г.И. и др. Факторы риска сердечно-сосудистых заболеваний у больных с синдромом обструктивного апноэ сна. Клиницист 2014;(1):15–21.Маркин А.В., Мартыненко Т.И., Костюченко Г.И. и др. Факторы риска сердечно-сосудистых заболеваний у больных с синдромом обструктивного апноэ сна. Клиницист 2014;(1):15–21.3. Пизова Н.В., Дружинин Д.С. Атеросклеротическое поражение сонных артерий у пациентов молодого возраста. Клиницист 2014;(1):28–33.Пизова Н.В., Дружинин Д.С. Атеросклеротическое поражение сонных артерий у пациентов молодого возраста. Клиницист 2014;(1):28–33.4. Ge Y., Wang T.J. Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med 2012;272(5):430–9.Ge Y., Wang T.J. Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med 2012;272(5):430–9.5. Zannad F., De Backer G., Graham I. et al.; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol 2012;26(2):163–74.Zannad F., De Backer G., Graham I. et al.; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol 2012;26(2):163–74.6. Mureddu G.F., Brandimarte F., Faggiano P. et al. Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice? Eur Heart J Cardiovasc Imaging 2013;14(5):401–16.Mureddu G.F., Brandimarte F., Faggiano P. et al. Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice? Eur Heart J Cardiovasc Imaging 2013;14(5):401–16.7. McQueen M.J., Hawken S., Wang X. et al. INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a casecontrol study. Lancet 2008;372(9634):224–33.McQueen M.J., Hawken S., Wang X. et al. INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a casecontrol study. Lancet 2008;372(9634):224–33.8. Walldius G., Jungner I., Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358(9298):2026–33.Walldius G., Jungner I., Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358(9298):2026–33.9. van der Steeg W.A., Boekholdt S.M., Stein E.A. et al. Role of the apolipoproteinB-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146(9):640–8.van der Steeg W.A., Boekholdt S.M., Stein E.A. et al. Role of the apolipoproteinB-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146(9):640–8.10. Nordestgaard B.G., Chapman M.J., Ray K. et al.; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844–53.Nordestgaard B.G., Chapman M.J., Ray K. et al.; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844–53.11. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340(2):115–26.Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340(2):115–26.12. Hlatky M.A., Greenland P., Arnett D.K. et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119(17): 2408–16.Hlatky M.A., Greenland P., Arnett D.K. et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119(17): 2408–16.13. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297(6): 611–9.Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297(6): 611–9.14. Krintus M., Kozinski M., Kubica J., Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci 2014: 1–17. [Epub ahead of print].Krintus M., Kozinski M., Kubica J., Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci 2014: 1–17. [Epub ahead of print].15. Everett B.M., Pradhan A.D., Solomon D.H. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166(2):199–207. e15.Everett B.M., Pradhan A.D., Solomon D.H. et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166(2):199–207. e15.16. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 2011;162(4):597–605.Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 2011;162(4):597–605.17. Toth P.P., McCullough P.A., Wegner M.S., Colley K.J. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther 2010;8(3):425–38.Toth P.P., McCullough P.A., Wegner M.S., Colley K.J. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther 2010;8(3):425–38.18. Cai A., Zheng D., Qiu R. et al. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers 2013;34(5):323–31.Cai A., Zheng D., Qiu R. et al. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers 2013;34(5):323–31.19. Ballantyne C.M., Hoogeveen R.C., Bang H. et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109(7): 837–42.Ballantyne C.M., Hoogeveen R.C., Bang H. et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109(7): 837–42.20. Nambi V., Hoogeveen R.C., Chambless L. et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009;40(2):376–81.Nambi V., Hoogeveen R.C., Chambless L. et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009;40(2):376–81.21. Lorenz M.W., Markus H.S., Bots M.L. et al. Prediction of clinical cardiovascular events with carotid intima–media thickness: a systematic review and meta-analysis. Circulation 2007;115(4):459–67.Lorenz M.W., Markus H.S., Bots M.L. et al. Prediction of clinical cardiovascular events with carotid intima–media thickness: a systematic review and meta-analysis. Circulation 2007;115(4):459–67.22. Гайсенок О.В., Марцевич С.Ю. Толщина интима–медиа – предиктор выявления ишемической болезни сердца и независимый фактор риска развития сердечно-сосудистых событий. Клиницист 2011;(4):5–9.Гайсенок О.В., Марцевич С.Ю. Толщина интима–медиа – предиктор выявления ишемической болезни сердца и независимый фактор риска развития сердечно-сосудистых событий. Клиницист 2011;(4):5–9.23. Lorenz M.W., Schaefer C., Steinmetz H., Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS) Eur Heart J 2010;31(16):2041–8.Lorenz M.W., Schaefer C., Steinmetz H., Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS) Eur Heart J 2010;31(16):2041–8.24. Costanzo P., Perrone-Filardi P., Vassallo E. et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010;56(24): 2006–20.Costanzo P., Perrone-Filardi P., Vassallo E. et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010;56(24): 2006–20.25. McEvoy J.W., Blaha M.J., Defilippis A.P. et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol 2010;56(20):1613–22.McEvoy J.W., Blaha M.J., Defilippis A.P. et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol 2010;56(20):1613–22.26. Rozanski A., Gransar H., Shaw L.J. et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing The EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 2011;57(15):1622–32.Rozanski A., Gransar H., Shaw L.J. et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing The EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 2011;57(15):1622–32.27. Perk J., De Backer G., Gohlke H. et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33(13):1635–701.Perk J., De Backer G., Gohlke H. et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33(13):1635–701.28. Кардиоваскулярная профилактика. Национальные рекомендации. Кардиоваскул тер и профил 2011;10(6 Прил 2):3–64.Кардиоваскулярная профилактика. Национальные рекомендации. Кардиоваскул тер и профил 2011;10(6 Прил 2):3–64.29. Бойцов С.А., Шальнова С.А., Деев А.Д., Калинина А.М. Моделирование риска развития сердечно-сосудистых заболеваний и их осложнений на индивидуальном и групповом уровнях. Тер архив 2013;85(9):4–10.Бойцов С.А., Шальнова С.А., Деев А.Д., Калинина А.М. Моделирование риска развития сердечно-сосудистых заболеваний и их осложнений на индивидуальном и групповом уровнях. Тер архив 2013;85(9):4–10.30. Greenland P., Alpert J.S., Beller G.A. et al.; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic dults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56(25):e50–103.Greenland P., Alpert J.S., Beller G.A. et al.; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic dults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56(25):e50–103.31. Goff D.C. Jr., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2935–59.Goff D.C. Jr., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2935–59.